{"id":425,"date":"2018-04-03T09:51:22","date_gmt":"2018-04-03T09:51:22","guid":{"rendered":"http:\/\/haema-journal.gr\/?p=425"},"modified":"2018-04-24T19:58:25","modified_gmt":"2018-04-24T19:58:25","slug":"anaplastic-large-cell-lymphoma-alk","status":"publish","type":"post","link":"https:\/\/haema-journal.gr\/?p=425","title":{"rendered":"Anaplastic large cell lymphoma (ALK+\/-)"},"content":{"rendered":"<p style=\"text-align: right;\"><em>Haema 2010; 1(1): 29-41<\/em><\/p>\n<p>by G.Z. Rassidakis<sup>1<\/sup> and T.P. Vassilakopoulos<sup>2<\/sup><\/p>\n<p><sup>1<\/sup>1st Department of Pathology, National and Kapodistrian University of \u0391thens, Adjunct AssistantProfessor of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA,<br \/>\n<sup>2<\/sup>Haematology Clinic, National and Kapodistrian University of Athens<\/p>\n<p style=\"text-align: right;\"><a href=\"http:\/\/haema-journal.gr\/PDF\/2010\/HAEMA_2010-29.pdf\" target=\"_blank\" rel=\"noopener\">Full PDF (in Greek)<\/a> | <a href=\"http:\/\/haema-journal.gr\/PDF\/2010\/HAEMA_2010-29.pdf\" target=\"_blank\" rel=\"noopener\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-390 size-full\" src=\"http:\/\/haema-journal.gr\/wp-content\/uploads\/2018\/02\/PDF-icon.jpg\" alt=\"\" width=\"36\" height=\"36\" \/><\/a><\/p>\n<p> <!--more--><\/p>\n<h5><strong>Abstract<\/strong><\/h5>\n<p style=\"text-align: justify;\">In the recent WHO classification, anaplastic large cell lymphoma (ALCL) is further classified, based on Anaplastic Lymphoma Kinase (ALK) expression, into a clearly established entity (ALK+ ALCL) and a provisional entity (ALK- ALCL). The expression of ALK is the consequence of chromosomal abnormalities involving the alk gene at 2p23, most frequently t(2;5)(p23;q35). Despite clinical and morphologic similarities, ALK+ and ALK- ALCL differ with respect to demographic characteristics, molecular findings and prognosis. Except of typical morphology, ALCL is characterized by CD30 expression. Although ALCL is of T-cell origin, T-cell markers are not expressed in a considerable number of cases at the immunohistochemical level (Null phenotype). CHOP combination chemotherapy is the usual treatment of ALCL in adults. The addition of etoposide (CHOEP) or time intensification (CHOP- 14) may benefit patients &lt;60 and &gt;60 years old respectively. Younger patients with ALK- disease and age-adjusted IPI 2-3 probably benefit from high dose therapy and autologous stem cell transplantation in 1st remission. New agents appear to be active in relapsed\/refractory T-cell lymphomas, but experience in the specific setting of ALCL is still very limited (pralatrexate, denileukin diftitox, depsipeptide etc). Anti-CD30 targeted therapy is currently under clinical evaluation, while ALK targeting has not still entered clinical trials. Conventional prognostic factors include IPI and ALK expression. However, biological markers (survivin, bcl-2, MUC-1, CD56 etc) may further facilitate prognostication, if prospectively validated.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Haema 2010; 1(1): 29-41 by G.Z. Rassidakis1 and T.P. Vassilakopoulos2 11st Department of Pathology, National and Kapodistrian University of \u0391thens, Adjunct AssistantProfessor of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2Haematology Clinic, National and Kapodistrian University of Athens Full PDF (in Greek) |<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[36],"tags":[],"class_list":["post-425","post","type-post","status-publish","format-standard","hentry","category-haema-2010-1"],"_links":{"self":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts\/425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=425"}],"version-history":[{"count":4,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts\/425\/revisions"}],"predecessor-version":[{"id":773,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=\/wp\/v2\/posts\/425\/revisions\/773"}],"wp:attachment":[{"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/haema-journal.gr\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}